33043-37-7

Usage

Uses

Used in Pharmaceutical Research and Development:
(R)-N-ACETYL-3,4-DIMETHOXYPHENYLALANINE is utilized as a key component in the research and development of new pharmaceuticals, particularly for its potential role in the treatment of neurological disorders. Its ability to inhibit enzymes involved in neurotransmitter biosynthesis makes it a promising candidate for drug discovery and therapeutic intervention.
Used in Neurological Disorder Treatment:
In the field of neurology, (R)-N-ACETYL-3,4-DIMETHOXYPHENYLALANINE is used as a therapeutic agent for the treatment of neurological disorders. Its enzyme-inhibiting properties allow it to modulate neurotransmitter levels, which can be beneficial in managing the symptoms and progression of certain neurological conditions.
Used in Anti-Inflammatory and Antioxidant Applications:
(R)-N-ACETYL-3,4-DIMETHOXYPHENYLALANINE is employed as an anti-inflammatory and antioxidant agent, leveraging its inherent properties to reduce inflammation and oxidative stress in the body. This makes it a valuable compound in the development of treatments for conditions where inflammation and oxidative stress play a significant role in disease progression.
Used in Biotechnology:
In the biotechnology industry, (R)-N-ACETYL-3,4-DIMETHOXYPHENYLALANINE is used as a versatile compound for various applications, including the development of novel bioactive molecules and the enhancement of existing therapeutic agents. Its multifaceted properties make it a valuable asset in the creation of innovative solutions for a range of health-related challenges.

Upstream product

• 76313-28-5 2-acetylamino-3-(3,4-dimethoxy-1-phenyl)-2-propenoic acid 
• 38879-47-9 (Z)-4-(3,4-dimethoxybenzylidene)-2-methyl-5(4H)-oxazolone 
• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 41888-65-7 4-(3,4-dimethoxybenzylidene)-2-methyloxazol-5(4H)-one 

Relevant academic research and scientific papers

Asymmetric synthesis of unnatural amino acids and tamsulosin chiral intermediate

An efficient and enantioselective hydrogenation of N-acetylamino phenyl acrylic acids was successfully developed by using ruthenium catalyst. This methodology is important in the field of pharmaceuticals and provides a new process for the preparation of unnatural amino acids and tamsulosin chiral intermediate.

Asymmetric hydrogenation - Influence of the structure of carbohydrate derived catalysts on the relative enantioselectivity Q(H/Me) regarding acid and ester substrates and its inversion - Selectivity increase in water by amphiphiles

4,6-O-Benzylidene protected 2,3-bis(O-diphenylphosphino)-D-glycopyranoside rhodium(I) chelate precatalysts 1-4 e,f showed for the hydrogenation of methyl (Z)2-N-acylamidoacrylates 6-8 a stepwise decrease of the enantioselectivity with increasing number of axially oriented hexopyranoside substituents. The decrease is even stronger for the analogous substrate acids 6h-8h resulting in an unusual low relative enantioselectivity Q = q(H)/q(Me) of 0.3 for the precatalysts 4e and 4f. Deprotected, 4,6-OH-group bearing catalysts 1-4 g,h generally show smaller differences of %ee in methanol or benzene, however, not in water. Under addition of amphiphiles a in comparison with blanks b the relative enantioselectivity Q = q(a)/q(b) clearly increases for both groups of catalysts in most cases to Q-values between 3 up to 8 - independent of a neutral or ionic nature of the amphiphile.

Synthesis and application of (3R,4R)-3,4-bis(diphenylphosphino)tetrahydrofuran as ligand for asymmetric hydrogenation of acrylic acids

A new, chiral bisphosphine, (3R,4R)-3,4-bis(diphenylphosphino)tetrahydrofuran (4), is synthesized in three steps from (R,R)-tartaric acid esters. With rhodium(I) complexes of 4 enantiomeric excesses of 54 to 97% are obtained on catalytic hydrogenation of 2-(acetylamino)acrylic acid, 2-(acetylamino)cinnamic acids and itaconic acid. The applied substrate/catalyst ratios were between 250:1 and 11,000:1.